Burden of disease in Brazil, 1990-2016: a systematic subnational analysis for the Global Burden of Disease Study 2016

Carregando...
Imagem de Miniatura
Citações na Scopus
230
Tipo de produção
article
Data de publicação
2018
Título da Revista
ISSN da Revista
Título do Volume
Editora
ELSEVIER SCIENCE INC
Autores
MARINHO, Fatima
PASSOS, Valeria Maria de Azeredo
MALTA, Deborah Carvalho
FRANCA, Elizabeth Barboza
ABREU, Daisy M. X.
ARAUJO, Valdelaine E. M.
BUSTAMANTZ-TEIXEIRA, Maria Teresa
CAMARGOS, Paulo A. M.
CUNHA, Carolina Candida da
DUNCAN, Bruce Bartholow
Citação
LANCET, v.392, n.10149, p.760-775, 2018
Projetos de Pesquisa
Unidades Organizacionais
Fascículo
Resumo
Background Political, economic, and epidemiological changes in Brazil have affected health and the health system. We used the Global Burden of Disease Study 2016 (GBD 2016) results to understand changing health patterns and inform policy responses. Methods We analysed GBD 2016 estimates for life expectancy at birth (LE), healthy life expectancy (HALE), all-cause and cause-specific mortality, years of life lost (YLLs), years lived with disability (YLDs), disability-adjusted life-years (DALYs), and risk factors for Brazil, its 26 states, and the Federal District from 1990 to 2016, and compared these with national estimates for ten comparator countries. Findings Nationally, LE increased from 68.4 years (95% uncertainty interval [UI] 68.0-68.9) in 1990 to 75.2 years (74.7-75.7) in 2016, and HALE increased from 59.8 years (57.1-62.1) to 65.5 years (62.5-68.0). All-cause age-standardised mortality rates decreased by 34.0% (33.4-34.5), while all-cause age-standardised DALY rates decreased by 30.2% (27.7-32.8); the magnitude of declines varied among states. In 2016, ischaemic heart disease was the leading cause of age-standardised YLLs, followed by interpersonal violence. Low back and neck pain, sense organ diseases, and skin diseases were the main causes of YLDs in 1990 and 2016. Leading risk factors contributing to DALYs in 2016 were alcohol and drug use, high blood pressure, and high body-mass index. Interpretation Health improved from 1990 to 2016, but improvements and disease burden varied between states. An epidemiological transition towards non-communicable diseases and related risks occurred nationally, but later in some states, while interpersonal violence grew as a health concern. Policy makers can use these results to address health disparities.
Palavras-chave
Referências
  1. Ali S, 2017, PLOS NEGLECT TROP D, V11, DOI 10.1371/journal.pntd.0005135
  2. [Anonymous], 2017, Rev Bras Epidemiol, V20Suppl 01, P4, DOI 10.1590/1980-5497201700050002
  3. Aquino R, 2009, AM J PUBLIC HEALTH, V99, P87, DOI 10.2105/AJPH.2007.127480
  4. Bacchieri G, 2011, REV SAUDE PUBL, V45, P949, DOI [10.1590/S0034-89102011005000069, 10.1590/s0034-89102011005000069]
  5. Barreto SM, 2005, EPIDEMIOL SERV SAUDE, V14, P41
  6. Barros FC, 2010, AM J PUBLIC HEALTH, V100, P1877, DOI 10.2105/AJPH.2010.196816
  7. Bastos ML, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0182336
  8. Blencowe H, 2012, LANCET, V379, P2162, DOI 10.1016/S0140-6736(12)60820-4
  9. Blumenberg C, 2018, INJURY PREV, V24, P250, DOI 10.1136/injuryprev-2017-042473
  10. Brant Luisa Campos Caldeira, 2017, Rev. bras. epidemiol., V20, P116, DOI 10.1590/1980-5497201700050010
  11. Carneiro-Proietti AB, 2010, TRANSFUSION, V50, P918, DOI 10.1111/j.1537-2995.2009.02529.x
  12. Carvalho L, GROWTH DISTRIBUTION
  13. Cavalcante TM, 2017, CAD SAUDE PUBLICA, V33, DOI 10.1590/0102-311X00138315
  14. Costa KS, 2016, CAD SAUDE PUBLICA, V32, DOI 10.1590/0102-311X00090014
  15. Barros MBD, 2016, INT J EQUITY HEALTH, V15, DOI 10.1186/s12939-016-0439-0
  16. Duncan BB, 2017, DIABETOL METAB SYNDR, V9, DOI 10.1186/s13098-017-0216-2
  17. Emmerick Isabel Cristina Martins, 2015, J Pharm Policy Pract, V8, P10, DOI 10.1186/s40545-015-0030-x
  18. Escorel S, 2007, REV PANAM SALUD PUBL, V21, P164
  19. FRIES JF, 1980, NEW ENGL J MED, V303, P130, DOI 10.1056/NEJM198007173030304
  20. Fullman N, 2017, LANCET, V390, P1423, DOI 10.1016/S0140-6736(17)32336-X
  21. Gakidou E, 2017, LANCET, V390, P1345, DOI 10.1016/S0140-6736(17)32366-8
  22. Galvao J, 2002, LANCET, V360, P1862, DOI 10.1016/S0140-6736(02)11775-2
  23. Gomez-Dantes H, 2016, LANCET, V388, P2386, DOI 10.1016/S0140-6736(16)31773-1
  24. Hay SI, 2017, LANCET, V390, P1260, DOI 10.1016/S0140-6736(17)32130-X
  25. Homma A, 2013, VACCINE, V31, pB54, DOI 10.1016/j.vaccine.2012.11.084
  26. Instituto Brasileiro de Geografia e Estatistica, 2016, FROT MUN VEIC NO BRA
  27. Ladeira Roberto Marini, 2017, Rev. bras. epidemiol., V20, P157, DOI 10.1590/1980-5497201700050013
  28. Lanzieri TM, 2011, INT J INFECT DIS, V15, pE206, DOI 10.1016/j.ijid.2010.11.007
  29. Leal MD, 2016, REPROD HEALTH, V13, DOI 10.1186/s12978-016-0230-0
  30. Leal MD, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0155511
  31. Levy D, 2012, PLOS MED, V9, DOI 10.1371/journal.pmed.1001336
  32. Lotto Persio S, NON TRADITIONAL REF
  33. Lotufo PA, 2009, INT J STROKE, V4, P40, DOI 10.1111/j.1747-4949.2009.00240.x
  34. Macinko J, 2012, INT J EQUITY HEALTH, V11, DOI 10.1186/1475-9276-11-33
  35. Malta Deborah Carvalho, 2017, Rev. bras. epidemiol., V20, P142, DOI 10.1590/1980-5497201700050012
  36. Malta DC, 2016, INT J EQUITY HEALTH, V15, DOI 10.1186/s12939-016-0427-4
  37. Malta DC, 2011, EPIDEMIOL SERV SAUDE, V20, P425, DOI 10.5123/S1679-49742011000400002
  38. Malta Deborah Carvalho, 2015, Rev. bras. epidemiol., V18, P214, DOI 10.1590/1980-5497201500060019
  39. Malta DC, 2015, EPIDEMIOL SERV SAUDE, V24, P373, DOI 10.5123/S1679-49742015000300004
  40. Malta DC, 2012, LANCET, V380, P195, DOI 10.1016/S0140-6736(12)61041-1
  41. de Souza MDM, 2007, HEALTH AFFAIR, V26, P575, DOI 10.1377/hlthaff.26.2.575
  42. Ministerio da Saude, 2017, VIG BRAZ 2016 PRIV H
  43. Ministerio da Saude (BR), 2007, VIG BRAS 2006 VIG FA
  44. Monteiro CA, 2015, PUBLIC HEALTH NUTR, V18, P2311, DOI 10.1017/S1368980015002165
  45. Murray CJL, 2012, LANCET, V380, P2063, DOI 10.1016/S0140-6736(12)61899-6
  46. Murray J, 2013, AGGRESS VIOLENT BEH, V18, P471, DOI 10.1016/j.avb.2013.07.003
  47. Naghavi M, 2017, LANCET, V390, P1151, DOI 10.1016/S0140-6736(17)32152-9
  48. Newton JN, 2015, LANCET, V386, P2257, DOI 10.1016/S0140-6736(15)00195-6
  49. Nilson EAF, 2017, NUTRIENTS, V9, DOI 10.3390/nu9070742
  50. Nomura S, 2017, LANCET, V390, P1521, DOI 10.1016/S0140-6736(17)31544-1
  51. Paim J, 2011, LANCET, V377, P1778, DOI 10.1016/S0140-6736(11)60054-8
  52. Paim JS, 2013, CAD SAUDE PUBLICA, V29, P1927, DOI 10.1590/0102-311X00099513
  53. PNUD Brazilian Cooperation Agency, NON TRADITIONAL REF
  54. Rasella D, 2014, BMJ-BRIT MED J, V349, DOI 10.1136/bmj.g4014
  55. Reichenheim ME, 2011, LANCET, V377, P1962, DOI 10.1016/S0140-6736(11)60053-6
  56. Reitsma MB, 2017, LANCET, V389, P1885, DOI 10.1016/S0140-6736(17)30819-X
  57. Ribeiro ALP, 2016, CIRCULATION, V133, P422, DOI 10.1161/CIRCULATIONAHA.114.008727
  58. Salomon JA, 2015, LANCET GLOB HEALTH, V3, pE712, DOI 10.1016/S2214-109X(15)00069-8
  59. Skoufias E, 2017, NON TRADITIONAL REF
  60. Stevens GA, 2016, LANCET, V388, pE19, DOI 10.1016/S0140-6736(16)30388-9
  61. Victora CG, 2011, LANCET, V377, P2042, DOI 10.1016/S0140-6736(11)60055-X
  62. Victora CG, 2011, LANCET, V377, P1863, DOI 10.1016/S0140-6736(11)60138-4
  63. Vincens N, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0137332
  64. Vos T, 2017, LANCET, V390, P1211, DOI 10.1016/S0140-6736(17)32154-2
  65. Wang HD, 2017, LANCET, V390, P1084, DOI 10.1016/S0140-6736(17)31833-0
  66. Wong Laura L. Rodríguez, 2006, Rev. bras. estud. popul., V23, P5, DOI 10.1590/S0102-30982006000100002
  67. World Economic Forum, 2011, BURD BEST BUYS RED E
  68. World Health Organization, 2017, NON TRADITIONAL REF
  69. World Health Organization, 2018, GLOB HLTH EXP DAT
  70. Zhou MG, 2016, LANCET, V387, P251, DOI 10.1016/S0140-6736(15)00551-6